MedTrace Logo

A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C

NCT00332176 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2008-04-08

No results posted yet for this study

Summary

The objective of this study is to undertake an initial evaluation of the safety, tolerability, antiviral effect, and pharmacokinetics of celgosivir in combination with peginterferon alfa-2b and ribavirin in patients with chronic HCV infection.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

Celgosivir

400mg qd + standard of care for 12 weeks

DRUG

Celgosivir

600mg qd + standard of care for 12 weeks

DRUG

Peginterferon alfa 2b + ribavirin

Standard of care for 12 weeks

Sponsors & Collaborators

  • BioWest Therapeutics Inc

    lead INDUSTRY

Principal Investigators

  • Jim Pankovich · BioWest Therapeutics Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00332176 on ClinicalTrials.gov